Core Insights - NovoCure Ltd's shares surged 29.52% to $13.60 after the FDA approved Optune Pax for treating locally advanced pancreatic cancer [1] Group 1: FDA Approval and Product Details - The approval of Optune Pax marks the first new treatment for locally advanced pancreatic cancer in nearly 30 years [2] - Optune Pax is a portable device that delivers Tumor Treating Fields (TTFields) noninvasively and is approved for use with gemcitabine and nab-paclitaxel chemotherapy [2] Group 2: Clinical Trial Results - The PANOVA-3 trial evaluated Optune Pax in combination with gemcitabine and nab-paclitaxel against the same chemotherapy alone in 571 patients [3] - Median overall survival was 16.2 months for the combination treatment compared to 14.2 months for chemotherapy alone, indicating a two-month improvement with a hazard ratio of 0.82 (p=0.039) [4] - Time to pain progression was extended to 15.2 months compared to 9.1 months, with device-related skin reactions occurring in 76.3% of patients, mostly Grade 1 or 2 [4] Group 3: Trading Metrics and Market Position - NovoCure has a market capitalization of $1.18 billion, with a 52-week high of $22.95 and a low of $9.82, reflecting a 50.50% decline over the past year [5] - The stock is currently positioned about 5.2% above its 52-week low, indicating weak positioning despite short-term opportunities [6]

Novocure Q3 2025 earnings Thursday, October 30, 2025 Confidential © 2024 © 2025 NovocuNovocu re GmbH re GmbH 1 forward -looking statements In addition to historical facts or statements of current condition, this presentation may contain forward - looking statements. Fo rward - looking statements provide Novocure's current expectations or forecasts of future events. These may include statements regarding anticipated scientific pro gress on its research programs, clinical trial progress, development of potent ...